Sun Pharma's Halol facility issued eight observations by U.S. FDA
Sun Pharmaceutical Industries' drug manufacturing facility in Halol, Gujarat, has been issued eight observations by the U.S. Food and Drug Administration (FDA).
The U.S. FDA issued a Form-483 with eight observations following conclusion of a Good Manufacturing Practices (GMP) inspection of the facility from June 2-13, Sun Pharma said in a filing to the stock exchanges on Saturday.
'This is further to our update on Halol dated 16 December 2022,' the company said, referring to the warning letter the U.S. FDA had issued to the facility. The warning letter came close on the heels of regulator placing the Halol facility under import alert.
The warning letter had summarised violations with respect to current good manufacturing practice (cGMP) regulations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
a day ago
- The Hindu
Sun Pharma's Halol facility issued eight observations by U.S. FDA
Sun Pharmaceutical Industries' drug manufacturing facility in Halol, Gujarat, has been issued eight observations by the U.S. Food and Drug Administration (FDA). The U.S. FDA issued a Form-483 with eight observations following conclusion of a Good Manufacturing Practices (GMP) inspection of the facility from June 2-13, Sun Pharma said in a filing to the stock exchanges on Saturday. 'This is further to our update on Halol dated 16 December 2022,' the company said, referring to the warning letter the U.S. FDA had issued to the facility. The warning letter came close on the heels of regulator placing the Halol facility under import alert. The warning letter had summarised violations with respect to current good manufacturing practice (cGMP) regulations.
The Hindu
a day ago
- The Hindu
Natco Pharma's API plant in Hyderabad gets U.S. FDA observation
Generic drugmaker Natco Pharma's active pharmaceutical igredients (API) manufacturing plant in Mekaguda, Hyderabad, has been issued a Form 483 with one observation by the U.S. Food and Drug Administration. The U.S. FDA conducted the inspection from June 9-13, and on conclusion, the company received one observation in the Form-483. The company believes it is procedural in nature and is confident to address the observation comprehensively, Natco Pharma said in a filing on Friday.
Business Standard
a day ago
- Business Standard
NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit
NATCO Pharma said that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from 09 to 13 of June 2025. On conclusion of the inspection, the company received one observation in the Form-483. The company believes that the observation is procedural in nature. The company is confident to address this observation comprehensively. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The companys consolidated net profit increased 5.3% to Rs 406.60 crore on 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24. The scrip had declined 1.26% to end at Rs 912.55 on the BSE on Friday.
